Annexon Advances Neuroinflammatory Pipeline: ANX005, ANX007, and ANX1502 Lead the Charge
核心洞察
Annexon anticipates submitting a Biologics License Application (BLA) for ANX005 in the first half of 2025, marking it as a potential first targeted therapy for Guillain-Barré Syndrome (搜索).
Enrollment in the Phase 3 ARCHER II trial for ANX007, a neuroprotective therapy for Geographic Atrophy (搜索), is expected to be completed in the second half of 2025.
Clinical proof-of-concept data for ANX1502, the first oral C1s (搜索) inhibitor being developed for Cold Agglutinin Disease (搜索), is anticipated in the first quarter of 2025.
Annexon, Inc. (Nasdaq: ANNX) is making significant strides in its pipeline of novel therapies targeting classical complement-mediated neuroinflammatory diseases. With a focus on addressing unmet needs in conditions affecting the body, brain, and eye, Annexon is advancing three key programs: ANX005 for Guillain-Barré Syndrome (搜索) (GBS), ANX007 for Geographic Atrophy (搜索) (GA), and ANX1502 for Cold Agglutinin Disease (搜索) (CAD).
ANX005: Targeting Guillain-Barré Syndrome
ANX005, a potential first-in-class targeted therapy for GBS, is on track for a Biologics License Application (BLA) submission in the first half of 2025. This follows positive topline results from a real-world evidence study comparing ANX005 treatment to intravenous immunoglobulin (IVIg) or plasma exchange (PE) in a matched patient cohort. The study demonstrated early and greater benefits of ANX005 over standard treatments in muscle strength and functional outcomes.
ANX007: Neuroprotection in Geographic Atrophy
Annexon is actively enrolling patients in the Phase 3 ARCHER II trial for ANX007, a neuroprotective therapy aimed at slowing the progression of Geographic Atrophy (搜索) (GA). Topline data from the ARCHER II trial is expected in the second half of 2026. Prior Phase 2 data has shown that ANX007 provides significant vision protection in standard and low light conditions, along with preservation of photoreceptors in the fovea region, which is critical for visual acuity. These findings were presented at the Floretina-ICOOR 2024 Meeting and the American Academy of Ophthalmology 2024 Meeting.
ANX1502: Oral C1s Inhibitor for Cold Agglutinin Disease
ANX1502, a first-in-kind oral C1s (搜索) inhibitor, is progressing towards clinical proof-of-concept data in Cold Agglutinin Disease (搜索) (CAD), with results expected in the first quarter of 2025. The program has transitioned to an enhanced tablet formulation to optimize delivery and patient convenience.
Financial Outlook and Leadership
Annexon's financial runway extends into the second half of 2026, providing sufficient capital to achieve key milestones across its portfolio. The company recently expanded its Board of Directors with the appointment of William “BJ” Jones, a seasoned commercial executive with three decades of experience in the biotechnology industry. Additionally, Annexon has strengthened its senior leadership team with appointments in commercial, medical affairs, and health economics roles.